Literature DB >> 14999524

Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios.

Henrik L Jørgensen1, Philip Kusk, Bente Madsen, Mogens Fenger, Jes B Lauritzen.   

Abstract

The purpose of this study is to investigate the association of serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter with peripheral measures of bone mass and with odds ratios for wrist and hip fracture in a case-control study of postmenopausal Danish women. The study included 66 women with lower forearm fracture, 41 women with hip fracture, and 206 age-matched controls. All had broadband ultrasound attenuation (BUA) and speed of sound (SOS) measured at the heel as well as bone mineral density (BMD) measured by DXA at the distal forearm. S-OPG was measured by ELISA. The A163G genotypes were determined by PCR-RFLP analysis. S-OPG levels correlated positively with age ( r = 0.45; P << 0.0001) and negatively with distal forearm BMD ( r = -0.31; P << 0.0001), heel BUA ( r = -0.23; P << 0.0001), and heel SOS ( r = -0.22; P << 0.0001). Comparing the highest quartile of S-OPG to the lowest, the odds ratio for osteoporotic fracture was 2.5 (95% CI, 1.3-4.7; P = 0.006). The G allele of the A163G was associated with significantly lower t-scores of both lower forearm BMD, heel BUA, and heel SOS as well as being significantly more frequent in the fracture patients compared to the controls. Patients with a combination of the highest quartile of S-OPG and presence of the G allele ( n = 23) had a significantly elevated fracture odds ratio, 4.0 (95% CI, 1.7-9.9). A significant negative association between S-OPG with peripheral measures of bone mass and with increased fracture odds ratios was found. Furthermore, the A163G mutation in the OPG promoter had a significant influence on bone mass and fracture status independently of S-OPG level.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999524     DOI: 10.1007/s00774-003-0461-3

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  28 in total

1.  The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.

Authors:  Heba S Omar; Olfat G Shaker; Yasser H Nassar; Samar A Marzouk; Mohamed S ElMarzouky
Journal:  Mol Cell Biochem       Date:  2015-02-28       Impact factor: 3.396

2.  Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?

Authors:  P Rozas Moreno; R Reyes García; A García-Martín; M Varsavsky; J A García-Salcedo; M Muñoz-Torres
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

3.  Polymorphism in vitamin D receptor and osteoprotegerin genes in Egyptian rheumatoid arthritis patients with and without osteoporosis.

Authors:  Yousry Mostafa Hussien; Amal Shehata; Rehab A Karam; Saad S Alzahrani; Hanem Magdy; Abeer M El-Shafey
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

4.  Association of RANKL and OPG Gene Polymorphism in Arab Women with and without Osteoporosis.

Authors:  Saba Abdi; Rawan A Binbaz; Abdul Khader Mohammed; Mohammed G A Ansari; Kaiser Wani; Osama E Amer; Abdullah M Alnaami; Naji Aljohani; Nasser M Al-Daghri
Journal:  Genes (Basel)       Date:  2021-01-29       Impact factor: 4.096

5.  Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway.

Authors:  Qingtang Miao; Sibin Hao; Hongmei Li; Fang Sun; Xueling Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals.

Authors:  Todd T Brown; Yun Chen; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Michael P Dubé; Robert Murphy; James H Stein; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

7.  Association analyses of osteoprotegerin gene polymorphisms with bone mineral density in Chinese postmenopausal women.

Authors:  Feng Zhang; Chunlei He; Gang Chen; Fangcai Li; Hui Gao
Journal:  Med Oncol       Date:  2013-01-19       Impact factor: 3.064

8.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

9.  Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head.

Authors:  Ming-Yue Xiong; Li-Qiang Liu; Shi-Qiong Liu; Zhen-Hui Liu; Hang-Fei Gao
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

10.  Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis.

Authors:  Young Ho Lee; Jin-Hyun Woo; Seong Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Mol Biol Rep       Date:  2009-07-30       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.